Innovation1 Biotech (IVBT) Stock Price

Innovation1 Biotech Price

NYSE·CLOSED
0.00
​
Market closed

Revenue at Innovation1 Biotech has contracted by 43.2% per year over the past 3 years to 3,080.00 USD. Innovation1 Biotech's net margin stands at 33,764.0%, up from -5,816.7% several years earlier.

Innovation1 Biotech stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Innovation1 Biotech business model & stock analysis

Innovation1 Biotech, Inc. develops modified Schedule 1 molecules from botanical sources, creating synthetic derivatives for neurologic, psychiatric, dermatologic, and ophthalmologic disorders. The company offers five preclinical prodrugs: a mushroom-derived psychedelic prodrug for PTSD and depression, a cannabinoid and tree bark-derived psychedelic prodrug for addiction, and three cannabinoid prodrugs targeting refractory pediatric epilepsy, hypertrophic scarring, and ocular inflammation. These products are based on synthetic derivatives of natural molecules like psilocin from mushrooms and synthetic tetrahydrocannobivarin from Cannabis, with no botanical sourcing in the final products. The company's clients are pharmaceutical firms seeking novel treatments for complex conditions, focusing on neurologic and psychiatric applications. The first prodrug targets PTSD and depression using a synthetic psilocin derivative, while the second combines cannabinoid and tree bark elements for addiction treatment. The third prodrug addresses pediatric epilepsy, scarring, and eye inflammation through cannabinoid-based synthetic compounds. Innovation1 Biotech's revenue comes from licensing its preclinical compounds to pharmaceutical companies for further development and commercialization, with a focus on high-value therapeutic areas like mental health and rare diseases. The company's portfolio emphasizes synthetic chemistry without reliance on direct botanical extraction for its final drug candidates.

Frequently asked questions about Innovation1 Biotech

Converted at the current exchange rate, the Innovation1 Biotech share trades at 0.00 EUR (0.00 USD).

The revenue cannot currently be calculated for Innovation1 Biotech.

The profit cannot currently be calculated for Innovation1 Biotech.

The P/E ratio cannot be calculated for Innovation1 Biotech at the moment.

The P/S cannot be calculated for Innovation1 Biotech currently.

The Eulerpool Quality Score for Innovation1 Biotech is 5/10.

The ISIN of Innovation1 Biotech is US39809D2018. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Innovation1 Biotech is IVBT. The ticker symbol is used to trade Innovation1 Biotech shares on the stock exchange.

Fair ValueTerminal
0.00 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Pharmaceuticals
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website
Currency
USD
Initial public offering
Feb 6, 2017
ISIN
US39809D2018
Cusip
39809D201
Market capitalization
4,494.00 USDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/S
P/Se
—
EV/EBIT
—
P/B Ratio
0.00
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
186.49 %
Last updated Nov 22, 2026, 3:51 AM

Innovation1 Biotech Peer Group

Innovation1 Biotech Ticker

OTC · GMVP

Innovation1 Biotech FIGI

IVBT:US · BBG008H3TJD0IVBT:PQ · BBG008H3V0P5IVBT:UV · BBG008H3V0Q4